Global drug delivery company expands operations at Charnwood Campus
Global contract development and manufacturing organisation (CDMO) Kindeva Drug Delivery has expanded its operations at Loughborough’s life sciences hub Charnwood Campus, in a deal expected to support Kindeva’s continued growth in the UK.
The US-headquartered company will take over a state-of-the-art research and development facility at Charnwood Campus, and a further 20,000 square feet of office space at the site.
Formerly 3M Drug Delivery Systems, Kindeva specialises in solving complex drug delivery and combination product challenges for its pharmaceutical and biotechnology customers, and currently employs over 500 staff in the UK across its two sites at Charnwood Campus, its Loughborough plant, and its Clitheroe plant.
News | March 8, 2021
Viatris Inc. And Kindeva Drug Delivery Announce FDA Tentative Approval Of The First Abbreviated New Drug Application Generic Version Of Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol
Source: Kindeva Drug Delivery
Milestone reinforces Viatris commitment to complex products and innovative solutions to help increase patient access
PITTSBURGH and ST. PAUL, Minn., March 8, 2021 Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort
®
based on an Abbreviated New Drug Application (ANDA). Symbicort is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).
PITTSBURGH and ST. PAUL, Minn., March 8, 2021 /PRNewswire/ Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that the U.S. Food and Drug Administration (FDA) granted
Operator
Ladies and gentlemen, thank you for standing by and welcome to Columbia Banking System s Fourth Quarter and Full Year 2020 Earnings Update. [Operator Instructions] I would now like to turn the call over to your host, Clint Stein, President and Chief Executive Officer of Columbia Banking System. Please go ahead, sir.
Clint Stein
President and Chief Executive Officer
Thank you. Carmen. Welcome and good morning, everyone. I thank you for joining us on today s call as we review our fourth quarter and full year 2020 results. Our earnings release and investor presentation are available at columbiabank.com.
Amidst the turmoil in 2020 caused by the pandemic, social unrest, turbulent financial markets, and contentious election cycle, Columbia achieved another record year. Pre-tax, pre-provision income of over $270 million was our best year yet, eclipsing in the record set just last year by $25 million. The pandemic drove our provision expense to credit losses to an all-time h